Victrex (LON:VCT)‘s stock had its “buy” rating reaffirmed by equities research analysts at UBS Group in a report released on Thursday, investing.thisismoney.co.uk reports. They presently have a GBX 3,200 ($41.81) target price on the stock, down from their previous target price of GBX 3,600 ($47.04). UBS Group’s price objective points to a potential upside of 38.53% from the company’s previous close.
Other equities research analysts have also issued reports about the company. Peel Hunt reissued an “add” rating on shares of Victrex in a research note on Tuesday. Liberum Capital restated a “buy” rating on shares of Victrex in a report on Tuesday, October 16th. Barclays restated an “underweight” rating and set a GBX 2,420 ($31.62) price objective on shares of Victrex in a report on Wednesday. Finally, Morgan Stanley downgraded Victrex to an “underweight” rating and reduced their price objective for the stock from GBX 2,500 ($32.67) to GBX 2,300 ($30.05) in a report on Friday, October 12th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. Victrex presently has an average rating of “Hold” and an average price target of GBX 2,527.73 ($33.03).
Shares of VCT stock opened at GBX 2,310 ($30.18) on Thursday. Victrex has a 52-week low of GBX 1,826 ($23.86) and a 52-week high of GBX 2,772 ($36.22).
Victrex Company Profile
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.
Further Reading: How accurate is the Rule of 72?
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.